Table 1.
Gene | ATLL Entire Japan [20] (n = 370) | ATLL North America [21] (n = 30) | ATLL Young Japanese [22] (n = 8) | PTCL-NOS [27] (n = 133) | AITL [27] (n = 26) | ALCL [27] (n = 23) | ENKTL [27] (n = 25) | HSTL [28] (n = 68) |
---|---|---|---|---|---|---|---|---|
PLCG1 | 36 | 0 | 0 | 8 | 8 | 0 | 0 | 6 |
PRKCB | 33 | NE | 13 | 0 | 0 | 0 | 0 | NA |
CCR4 | 29 | NE | 38 | 4 | 0 | 0 | 0 | 2 |
CARD11 | 24 | 7 | 38 | 3 | 0 | 0 | 0 | 2 |
STAT3 | 21 | 0 | 0 | 5 | 8 | 13 | 12 | 10 |
TP53 | 18 | 23 | 13 | 17 | 0 | 9 | 12 | 10 |
VAV1 | 18 | NE | 0 | 6 | 8 | 0 | 0 | NA |
TBL1XR1 | 17 | 13 | 0 | 4 | 0 | 0 | 0 | NA |
NOTCH1 | 15 | 20 | 25 | 5 | 0 | 0 | 0 | NA |
GATA3 | 15 | 7 | 0 | 0 | 0 | 0 | 0 | NA |
IRF4 | 14 | NE | 13 | 1 | 0 | 0 | 0 | 16 |
FAS | 11 | 0 | 0 | 4 | 0 | 4 | 0 | NA |
CCR7 | 11 | NE | 25 | 2 | 0 | 0 | 0 | NA |
POT1 | 10 | 7 | 0 | 2 | 4 | 4 | 0 | NA |
IRF2BP2 | 8 | NE | NE | 2 | 0 | 0 | 0 | NA |
TET2 | 8 | 7 | 13 | 43 | 88 | 4 | 0 | 6 |
RHOA | 8 | 3 | 13 | 26 | 81 | 0 | 0 | 2 |
HLA-B | 6 | NE | 0 | 5 | 4 | 4 | 0 | NA |
HNRNPA2B1 | 6 | NE | 0 | 0 | 0 | 4 | 0 | NA |
EP300 | 6 | 20 | 0 | 2 | 0 | 0 | 8 | NA |
CD58 | 5 | NE | 0 | 4 | 0 | 9 | 0 | 0 |
GPR183 | 5 | NE | NE | 1 | 0 | 0 | 0 | NA |
CSNK1A1 | 5 | NE | NE | 0 | 0 | 0 | 0 | NA |
CSNK2B | 5 | NE | NE | 1 | 0 | 0 | 0 | NA |
CBLB | 4 | NE | 0 | 0 | 0 | 0 | 0 | NA |
FYN | 4 | NE | 13 | 2 | 0 | 0 | 0 | 3 |
B2M | 4 | 0 | 0 | 5 | 8 | 0 | 0 | NA |
SETD2 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 22 |
ATLL, adult T-cell leukemia/lymphoma; PTCL, peripheral T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ENKTL, extranodal NK/T-cell lymphoma; HSTL, hepatosplenic T-cell lymphoma; NE, not evaluated; NA, not available.